MedElevator Войти в исследования
← Поиск публикаций

DOI 10.3346/jkms.2026.41.e184

Медицинская библиотека · Journal of Korean medical science · 2026

APOE Genotype Modifies the Predictive Performance of Plasma Biomarkers for Amyloid Plaque Burden in Subjective Cognitive Decline.

Lee Hyuk-Je, Yoon Bora, Hong Yun Jeong, Jeong Jee Hyang, Kim SangYun, Wang Min Jeong, Choi Seong Hye, Ryu Ji Sun, Kang Sungmin, Park Kee Hyung, Yang Dong Won

СтатьяПеревод в очереди

Аннотация

BACKGROUND

Apolipoprotein E (APOE) ε4 is a well-known risk factor for Alzheimer's disease (AD), with ε4 carriers exhibiting distinct clinical and biological characteristics compared to non-carriers. This study investigated whether the predictive performance of plasma biomarkers for amyloid positron emission tomography (PET) outcomes varies by APOE ε4 carrier status in individuals with subjective cognitive decline (SCD).

METHODS

We retrospectively analyzed baseline data from the Cohort Study to Identify Predictors for the Clinical Progression to Mild Cognitive Impairment or Dementia from Subjective Cognitive Decline. Plasma levels of the amyloid beta (Aβ) 42/40 ratio, glial fibrillary acidic protein (GFAP), neurofilament light chain (NfL), and phosphorylated tau (pTau) 181 were quantified using Single Molecule Array technology. We assessed predictive performance of plasma biomarkers for amyloid PET outcomes using receiver operating characteristic analysis and linear regression models.

RESULTS

The study included 104 participants, with 20 APOE ε4 carriers and 84 non-carriers. Among ε4 carriers, NfL (area under the curve [AUC] = 0.909), GFAP (AUC = 0.904), and pTau181 (AUC = 0.828) showed the highest predictive accuracy. For non-carriers, the most predictive biomarkers were pTau181/Aβ42 (AUC = 0.872), Aβ42/Aβ40 (AUC = 0.794), and pTau181 (AUC = 0.761). Significant interactions between APOE and biomarkers were noted for GFAP (P = 0.005) and NfL (P = 0.010) in predicting amyloid plaque burden.

CONCLUSION

Plasma biomarkers exhibit differential predictive performance for amyloid pathology based on APOE genotype, with GFAP and NfL showing interaction with APOE genotype. These findings suggest the importance of considering APOE genotype when interpreting plasma biomarker results for AD diagnosis in individuals with SCD.

TRIAL REGISTRATION: Clinical Research Information Service Identifier: KCT0003397.

Для цитирования: Lee Hyuk-Je, Yoon Bora, Hong Yun Jeong, Jeong Jee Hyang, Kim SangYun, Wang Min Jeong, Choi Seong Hye, Ryu Ji Sun, Kang Sungmin, Park Kee Hyung, Yang Dong Won. APOE Genotype Modifies the Predictive Performance of Plasma Biomarkers for Amyloid Plaque Burden in Subjective Cognitive Decline.. Journal of Korean medical science. 2026. DOI: 10.3346/jkms.2026.41.e184.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.